CG Labz
Peptide Library / Metabolic / Weight Management

Adipotide (FTPP)

Prohibitin-targeting peptide

Adipotide (FTPP) Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

Adipotide is a pro-apoptotic peptidomimetic (a prohibitin-targeting peptide fused to a KLAKLAK pro-apoptotic motif) that selectively targets the blood-vessel supply of white adipose tissue. In primate studies it produced rapid, substantial fat loss by pruning adipose vasculature.

Reconstitution
Add 2.0 mL bacteriostatic water to a 5 mg vial → 2.5 mg/mL
Measuring Reference
At 2.5 mg/mL: 500 mcg = 0.2 mL = 20 units
Frequency
Per study design
Route (studies)
Subcutaneous
Class
Pro-apoptotic peptidomimetic
Caution
Renal effects reported

Scientific Data

Molecular Formula
—
Molecular Weight
2622 Da
Sequence
CKGGRAKDC-GG-D(KLAKLAK)2
Sequence Length
19
CAS
Research compound
Peptide Family
Peptidomimetic
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 5 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
2.50 mg/mL
Draw Volume
0.200 mL
Syringe Units
20.0 U
Doses / Vial
10

Units assume a U-100 insulin syringe (100 units = 1 mL). An experimental oncology-derived agent — the most caution of any compound here.

Frequency: Per study design

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 4-week protocol at approximately 500 mcg per day.

Peptide (5 mg vials)
Estimate vials from total mass: 500 mcg/day × 28 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model targeted adipose-vasculature apoptosis.
Schedule
Short research courses.
Dose Range
Per study design only.

Dosing Protocol

Protocol (animal)
Short dosing courses studied in primates
Frequency
Per study design
Cycle Length
Short courses
Route
Subcutaneous in studies
Caution
Renal monitoring emphasised in literature
Status
Experimental research only

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • No human safety data exists. This is among the most experimental compounds in the catalog.
  • Renal effects are the principal documented concern.

How This Works

Adipotide homes to prohibitin on the endothelial cells that line the capillaries feeding white fat, then triggers targeted apoptosis of that vasculature. Starving the fat tissue of its blood supply causes adipocytes to shrink and the animal to lose fat mass. Because the target is vascular rather than metabolic, the mechanism is distinct from incretin or lipolytic agents.

Potential Benefits & Side Effects

Reported in research
  • Rapid, pronounced fat-mass reduction in primate studies
  • Targets adipose-tissue vasculature selectively
  • Improved insulin sensitivity accompanying fat loss in models
Possible considerations
  • Renal effects observed in animal studies (kidney is a research concern)
  • This is an experimental oncology-derived agent with no human safety profile
  • Injection-site reactions
  • Not characterised for human use — strictly research

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Science Translational Medicine
    Barnhart K.F. et al. A peptidomimetic targeting white fat causes weight loss in obese monkeys.
    View Source